Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix |
Domain |
PF15362 Enamelin |
Function |
Involved in the mineralization and structural organization of enamel. Involved in the extension of enamel during the secretory stage of dental enamel formation. |
Biological Process |
GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0022604 regulation of cell morphogenesis GO:0031214 biomineral tissue development GO:0034505 tooth mineralization GO:0036305 ameloblast differentiation GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0042481 regulation of odontogenesis GO:0042482 positive regulation of odontogenesis GO:0042487 regulation of odontogenesis of dentin-containing tooth GO:0042488 positive regulation of odontogenesis of dentin-containing tooth GO:0070166 enamel mineralization GO:0070167 regulation of biomineral tissue development GO:0070169 positive regulation of biomineral tissue development GO:0070170 regulation of tooth mineralization GO:0070172 positive regulation of tooth mineralization GO:0070173 regulation of enamel mineralization GO:0070175 positive regulation of enamel mineralization GO:0097186 amelogenesis GO:2000027 regulation of organ morphogenesis |
Molecular Function |
GO:0005201 extracellular matrix structural constituent GO:0030021 extracellular matrix structural constituent conferring compression resistance GO:0030345 structural constituent of tooth enamel |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ENAM and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ENAM in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ENAM in various data sets.
|
Points in the above scatter plot represent the mutation difference of ENAM in various data sets.
|
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENAM. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENAM. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENAM. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENAM. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ENAM expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ENAM |
Name | enamelin |
Aliases | AIH2; amelogenesis imperfecta 2, hypocalcification (autosomal dominant); ADAI; AI1C |
Chromosomal Location | 4q13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ENAM and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |